Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
CD24 Ala57Val polymorphism predicts pathologic complete response to sequential anthracycline- and taxane-based neoadjuvant chemotherapy for primary breast cancer.
Marmé F, Werft W, Walter A, Keller S, Wang X, Benner A, Burwinkel B, Sinn P, Hug S, Sohn C, Bretz N, Moldenhauer G, Rupp C, Rupp AK, Biakhov MY, Bottini A, Friedrichs K, Khailenko VA, Manikhas GM, Ruiz A, Sánchez-Rovira P, Santoro A, Segui MA, Villena C, Lichter P, Kristiansen G, Altevogt P, Schneeweiss A. Marmé F, et al. Among authors: rupp ak. Breast Cancer Res Treat. 2012 Apr;132(3):819-31. doi: 10.1007/s10549-011-1759-9. Epub 2011 Sep 30. Breast Cancer Res Treat. 2012. PMID: 21960110 Clinical Trial.
Extracellular vesicle-mediated transfer of genetic information between the hematopoietic system and the brain in response to inflammation.
Ridder K, Keller S, Dams M, Rupp AK, Schlaudraff J, Del Turco D, Starmann J, Macas J, Karpova D, Devraj K, Depboylu C, Landfried B, Arnold B, Plate KH, Höglinger G, Sültmann H, Altevogt P, Momma S. Ridder K, et al. Among authors: rupp ak. PLoS Biol. 2014 Jun 3;12(6):e1001874. doi: 10.1371/journal.pbio.1001874. eCollection 2014 Jun. PLoS Biol. 2014. PMID: 24893313 Free PMC article.
Role of miR-34a as a suppressor of L1CAM in endometrial carcinoma.
Schirmer U, Doberstein K, Rupp AK, Bretz NP, Wuttig D, Kiefel H, Breunig C, Fiegl H, Müller-Holzner E, Zeillinger R, Schuster E, Zeimet AG, Sültmann H, Altevogt P. Schirmer U, et al. Among authors: rupp ak. Oncotarget. 2014 Jan 30;5(2):462-72. doi: 10.18632/oncotarget.1552. Oncotarget. 2014. PMID: 24497324 Free PMC article.
Extracellular vesicle-mediated transfer of functional RNA in the tumor microenvironment.
Ridder K, Sevko A, Heide J, Dams M, Rupp AK, Macas J, Starmann J, Tjwa M, Plate KH, Sültmann H, Altevogt P, Umansky V, Momma S. Ridder K, et al. Among authors: rupp ak. Oncoimmunology. 2015 Mar 19;4(6):e1008371. doi: 10.1080/2162402X.2015.1008371. eCollection 2015 Jun. Oncoimmunology. 2015. PMID: 26155418 Free PMC article.
AMPLIFY-NEOVAC: a randomized, 3-arm multicenter phase I trial to assess safety, tolerability and immunogenicity of IDH1-vac combined with an immune checkpoint inhibitor targeting programmed death-ligand 1 in isocitrate dehydrogenase 1 mutant gliomas.
Bunse L, Rupp AK, Poschke I, Bunse T, Lindner K, Wick A, Blobner J, Misch M, Tabatabai G, Glas M, Schnell O, Gempt J, Denk M, Reifenberger G, Bendszus M, Wuchter P, Steinbach JP, Wick W, Platten M. Bunse L, et al. Among authors: rupp ak. Neurol Res Pract. 2022 May 23;4(1):20. doi: 10.1186/s42466-022-00184-x. Neurol Res Pract. 2022. PMID: 35599302 Free PMC article.
INTERCEPT H3: a multicenter phase I peptide vaccine trial for the treatment of H3-mutated diffuse midline gliomas.
Grassl N, Sahm K, Süße H, Poschke I, Bunse L, Bunse T, Boschert T, Mildenberger I, Rupp AK, Ewinger MP, Lanz LM, Denk M, Tabatabai G, Ronellenfitsch MW, Herrlinger U, Glas M, Krex D, Vajkoczy P, Wick A, Harting I, Sahm F, von Deimling A, Bendszus M, Wick W, Platten M. Grassl N, et al. Among authors: rupp ak. Neurol Res Pract. 2023 Oct 19;5(1):55. doi: 10.1186/s42466-023-00282-4. Neurol Res Pract. 2023. PMID: 37853454 Free PMC article.